News

Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor co-developed by AstraZeneca with Merck. Abiraterone is the standard-of-care treatment in mCRPC. The combination of Lynparza and abiraterone was evaluated

High risk of recurrence is defined as lymph node-positive or hormone receptor-negative disease. The Perjeta-based regimen should be administered for a total of one year (up to 18

MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced

The approval is for a 2mg dose of the drug in adult patients who did not show adequate response to one or more tumor necrosis factor (TNF) inhibitor

The interim data from the phase 2 KEYNOTE-427 study showed an ORR of 38.2% in patients who received Keytruda monotherapy as first-line therapy. It is the primary endpoint of

The partnership will assess the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax's oral, small molecule Class 1 specific HDAC inhibitor, in

Researchers want to discover whether AstraZeneca and MSD’s experimental medicine, selumetinib (AZD6244, ARRY-142886), can be effective in combination with dexamethasone, a treatment already used for several conditions including

The double-blind, placebo-controlled phase 2 study included 125 patients over the age of 18 and was undertaken across nearly 25 clinical sites in the US. Patients were randomized

The planned start of the Phase 1b/2 study (68284528MMY2001), scheduled to begin enrollment in the second half of 2018, follows the US Food and Drug Administration (FDA) clearance